S-1 withdrawal and clinical trial news fuel ADVB
S-1 withdrawal and clinical trial news fuel ADVB 27% premarket surge
- Withdrew Form S-1 on ~July 21 eliminating dilution risk from planned offering
- Terminated $25M equity purchase agreement effective July 21 removing overhang
- Promising clinical trial breakthroughs reported for cancer detection tech around July 22
- Nano/low float amplified momentum with massive volume on prior days
- Stock surged 70%+ on July 22 and 37% on July 23 before July 24 gap-up
- Continuation buying in premarket July 24 with no new PR identified
- Biotech focuses on liquid biopsy AI precision medicine and 3D cell platforms
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.